An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent
Rhea-AI Impact
(Moderate)
Rhea-AI Sentiment
(Very Positive)
Tags
Rhea-AI Summary
RenovoRx, Inc. (NASDAQ: RNXT) announced the issuance of US patent number 11,541,211 on January 3, 2023, covering methods for treating cholangiocarcinoma through targeted delivery of therapeutic agents. This patent is their eighth in the US, contributing to a robust intellectual property portfolio that includes 8 US method and device patents, one EU delivery system patent, and several pending patents globally. Additionally, the patent strengthens the seven years of market exclusivity RenovoRx holds for its lead product candidate, RenovoGem™, under FDA's Orphan Drug designation.
Positive
Issuance of US patent number 11,541,211 enhances RenovoRx's intellectual property portfolio.
The company now has eight US patents and additional pending patents, increasing its competitive edge.
Strengthens seven years of market exclusivity for RenovoGem™ due to Orphan Drug designation.
Negative
None.
Patent broadly covers methods for treating bile duct cancer.
LOS ALTOS, Calif.--(BUSINESS WIRE)--
RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced that on January 3, 2023 the United States Patent and Trademark Office issued US patent number 11,541,211 broadly covering methods for treating cholangiocarcinoma (bile duct cancer) by selectively delivering one or more therapeutic agents into targeted regions of the bile duct. This is RenovoRx’s eighth US patent.
"Our newest patent builds upon our strong IP portfolio, which now consists of eight US method and device patents, one EU delivery system patent, and eight additional pending patents in the US, EU, and Asia,” said Shaun Bagai, CEO of RenovoRx. “Additionally, this additional patent bolsters the seven years of post-approval market exclusivity that we currently have with our lead oncology product candidate, RenovoGem™, through the Orphan Drug designation granted by the FDA for our first two indications.”
About RenovoRx, Inc.
RenovoRx is a clinical-stage biopharmaceutical company with a vision to disrupt the current paradigm of cancer treatment. The company’s mission is to lead a revolution in oncology therapy by delivering its innovative and targeted intra-arterial (IA) delivery of chemotherapy directly to solid tumors. The proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform aims to avoid the harsh side effects typical of the current standard of care, thus improving patient well-being and extension of life so more time may be enjoyed with loved ones. RenovoTAMP utilizes approved chemotherapeutics with validated mechanisms of action and well-established safety and side effect profiles, with the goal of increasing their efficacy, improving their safety, and widening their therapeutic window. RenovoRx’s lead product candidate, RenovoGemTM, is a combination of gemcitabine and its patented delivery system, RenovoCath®, and is regulated by the FDA as a novel oncology drug product to treat unresectable locally advanced pancreatic cancer (LAPC). RenovoGem is currently being studied in the Phase III TIGeR-PaC trial for the treatment of LAPC.
RenovoRx’s patent portfolio for its therapy platform and product candidates includes eight issued U.S. patents, one issued European patent, and several additional patents pending in the US, EU and Asia. RenovoRx has been granted Orphan Drug Designation for intra-arterial delivery of gemcitabine for the treatment of both pancreatic cancer and bile duct cancer (cholangiocarcinoma).
Company Contact:
RenovoRx, Inc. Shaun R. Bagai, CEO
James Ahlers, CFO
Investor Contact:
KCSA Strategic Communications Valter Pinto or Jack Perkins T:212-896-1254
renovorx@kcsa.com
Source: RenovoRx, Inc.
FAQ
What is the significance of patent number 11,541,211 for RenovoRx (RNXT)?
Patent number 11,541,211 enhances RenovoRx's intellectual property by covering methods for treating cholangiocarcinoma, bolstering their competitive position.
How many patents does RenovoRx (RNXT) hold?
RenovoRx currently holds eight US patents, one EU patent, and has additional pending patents in various regions.
What is RenovoGem™ and its importance to RenovoRx (RNXT)?
RenovoGem™ is RenovoRx's lead oncology product candidate for treating locally advanced pancreatic cancer, benefiting from market exclusivity due to Orphan Drug designation.
When was the patent for treating bile duct cancer issued to RenovoRx (RNXT)?
The patent for treating bile duct cancer was issued on January 3, 2023.
